Meeting
2023 ASCO Annual Meeting
A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Authors
Dok Hyun Yoon
Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Dok Hyun Yoon , Hyungwoo Cho , Jae-Cheol Jo , Seong Hyun Jeong , Sung Yong Oh , Ki Hyun Kim , LeiGuang Cui , Tae-bum Lee , In-Sik Hwang , Young-Ha Lee , Yong-Jun Lee , Jong-Hoon Kim , Marco Ruella , Jong-Seo Lee , Junho Chung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT05338931
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7522)
DOI
10.1200/JCO.2023.41.16_suppl.7522
Abstract #
7522
Poster Bd #
73
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
First Author: Yang Xie
Poster
2016 ASCO Annual Meeting
A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (BâNHL).
First Author: Ki Y. Chung
Poster
2014 ASCO Annual Meeting
Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
First Author: Anastasios Stathis
Poster
2013 ASCO Annual Meeting
Phase I study of a novel humanized anti-CD20 antibody, BM-ca, in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab.
First Author: Kensei Tobinai